Cagrilintide (Appetite Control Peptide)

A long-acting amylin analogue studied for appetite regulation, satiety, and weight-management pathways.

Cagrilintide is an investigational amylin analogue designed to mimic and extend the activity of amylin—a naturally occurring hormone involved in signaling fullness after eating.

Why Cagrilintide?

🍽️ Appetite Regulation
Studied for its ability to influence appetite and food-intake signaling.

✨ Supports Satiety
Amylin pathways help communicate feelings of fullness between the body and brain.

⏳ Long-Acting Design
Cagrilintide was engineered for prolonged activity compared with naturally occurring amylin.

⚖️ Weight-Management Research
Clinical research has investigated cagrilintide both independently and alongside GLP-1–based therapies for body-weight management.

What Makes Cagrilintide Different?

Cagrilintide works through the amylin pathway, making it mechanistically different from GLP-1 medicines such as semaglutide and dual GIP/GLP-1 medicines such as tirzepatide.

Rather than simply being “another GLP-1,” its pharmacology centers on amylin receptors and satiety signaling—which is also why researchers have investigated combining amylin- and GLP-1–based approaches.

Product Details

Product: Cagrilintide
Category: Long-acting amylin analogue
Form: Lyophilized powder
Storage: Keep refrigerated at 2–8°C
Packaging: Individually sealed vial

For educational purposes. Cagrilintide is investigational and is not currently an approved medicine.